Sangamo Therapeutics, Inc.
NASDAQ:SGMOBiotechnology
+$0.00 today
- Market cap
- $70.43M
- Beta
- 1.29
- P/E (TTM)
- -0.5
- EPS (TTM)
- -$0.32
Volume 0.61M
Average 9.53M
SGMO Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Sangamo Therapeutics, Inc.NASDAQ: SGMO
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin declines year over year
Q1 FY2026 selling, general & admin of $6.82M fell 32.2% year over year, behind the -26.4% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 12.1% from the prior quarter. Over 3 fiscal years it compounded at -17.7% a year.
Context
- Selling, general & admin amounted to 88.2% of revenue in FY2025, up 10.8 pp from a year earlier.
- Selling, general & admin increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 1 analysts of $42.41M (+21.6%) for the fiscal year ending Dec 2026, a step up from the -22.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $6.82M-12.1% QoQ
- Last fiscal yearDec 2025
- $34.89M-22.0% YoY
- LTMMar 2026
- $31.65M-26.4% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 34.89M USD
- Year-over-year change
- -22.0%
- 4-year CAGR
- -13.8%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 34.89M | -22.0% |
| FY2024 | 2024-12-31 | 44.73M | -26.9% |
| FY2023 | 2023-12-31 | 61.17M | -2.4% |
| FY2022 | 2022-12-31 | 62.68M | -0.8% |
| FY2021 | 2021-12-31 | 63.22M | — |
Selling, General & Admin vs competitors
How SGMO compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -26.4% is the lowest of 11, against a peer median of -6.3%.
- Selling, general & admin amounts to 91.6% of revenue for SGMO, versus a peer median of 394.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $74.78M USD | +14.7% | +12.5% | 133.9% | |
| LTM Mar 2026 | $43.75M USD | -19.9% | -3.4% | 56.0% | |
| LTM Mar 2026 | $34.83M USD | -4.4% | -11.4% | 1952.5% | |
| LTM Mar 2026 | $34.4M USD | -16.4% | -5.4% | 98.7% | |
| LTM Mar 2026 | $31.65M USD | -26.4% | -17.7% | 91.6% | |
| LTM Mar 2026 | $26.47M USD | -12.7% | +5.5% | 91.6% | |
| LTM Mar 2026 | $19.01M USD | -17.8% | -9.7% | 599.8% | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | $17.81M USD | +22.1% | -7.6% | 914.0% |
| LTM Mar 2026 | CHF 16.11M CHF | -3.8% | -12.0% | — | |
| LTM Mar 2026 | $12.62M USD | -4.8% | +18.6% | 426.6% | |
| FY2025 | €11M EUR | -7.8% | -8.7% | 394.7% | |
| Peer median (excluding SGMO) | — | -6.3% | -6.5% | 394.7% | |
Competitors are the stored peer set for SGMO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 110.7M | 111.3M | 176.23M | 57.8M | 39.55M |
| Cost of Revenue | 0 | 12.11M | 0 | 0 | 7.6M |
| Gross Profit | 110.7M | 99.19M | 176.23M | 57.8M | 31.95M |
| Gross Margin | 100.0% | 89.1% | 100.0% | 100.0% | 80.8% |
| Research & Development | 230.82M | 249.9M | 234.06M | 111.52M | 112.67M |
| Selling, General & Admin | 63.22M | 62.68M | 61.17M | 44.73M | 34.89M |
| Operating Expenses | 294.04M | 300.47M | 450.24M | 161.77M | 139.95M |
| Depreciation & Amortization | 17.64M | 12.11M | 22.19M | 9.36M | 7.6M |
| EBITDA | (160.35M) | (179.74M) | (96.8M) | (89.09M) | (115.9M) |
| EBITDA Margin | -144.9% | -161.5% | -54.9% | -154.1% | -293.0% |
| Operating Income | (183.34M) | (201.28M) | (274.01M) | (103.97M) | (108M) |
| Operating Margin | -165.6% | -180.8% | -155.5% | -179.9% | -273.1% |
| Interest Income | 5.35M | 9.43M | 11.1M | 5.86M | 1.3M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 5.35M | 9.43M | 11.1M | 5.86M | (15.5M) |
| Income Before Tax | (177.99M) | (191.85M) | (262.9M) | (98.11M) | (123.5M) |
| Pre-Tax Margin | -160.8% | -172.4% | -149.2% | -169.7% | -312.2% |
| Income Tax Expense | 306K | 429K | (5.07M) | (167K) | (568K) |
| Net Income | (178.29M) | (192.28M) | (257.83M) | (97.94M) | (122.93M) |
| Net Margin | -161.1% | -172.8% | -146.3% | -169.4% | -310.8% |
| EPS (Basic) | (1.23) | (1.25) | (1.48) | (0.49) | (0.44) |
| EPS (Diluted) | (1.23) | (1.25) | (1.48) | (0.49) | (0.44) |
| Weighted Avg Shares | 144.57M | 154.35M | 174.44M | 201.7M | 280.19M |
| Weighted Avg Shares (Diluted) | 144.57M | 154.35M | 174.44M | 201.7M | 280.19M |
Sangamo Therapeutics, Inc.
NASDAQ:SGMO
Intrinsic Alpha fair value
Locked
Current Price
$0.18
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.